Insider trade

Officer sold ~$134K of NRIX shares in the open market

Traded Oct 2, 2026 · Filed Oct 2, 2026

~$134K
Approx. value · 5,786 sh @ $23.19: 9,110
Holds after · shares reported: −1.7%
Since filing · from the first close after the filing, $22.99 → $22.60 on Oct 6, S&P 500 +1.2%

Why it stands out

Nurix Therapeutics's Chief Legal Officer sold $134K of Nurix Therapeutics shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$134,149

Shares × reported transaction price

Timing vs results

85 days after results of Jul 9, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
Represents the weighted average sale price. The lowest price at which shares were sold was $22.84 and the highest price at which shares were sold was $23.65. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.